Ayers et al. (2017) confirmed the predictive usefulness of an IFN-γ-related mRNA profile for the response to pembrolizumab in melanomas. However, no predictive transcriptional biomarker has been established with validation in gliomas due to the scarcity of both pre-treatment tumor samples with sequencing data and associated clinical outcomes. In our study, we evaluated the predictive value of CARS in a recently published cohort of glioma patients treated with PD-1 inhibitors (Zhao et al., 2019). The gene discussed is IFNG; the disease is central nervous system cancer.